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NY-ESO-1 is one of the most immunogenic proteins described in
human cancers, based on its capacity to elicit simultaneous antibody
and CD8 T cell responses in vivo. Although HLA class II restricted
epitopes from NY-ESO-1 have been identified, no broad survey has
yet established the status of natural CD4 T cell responses in cancer
patients in relation to CD8 and antibody responses. We used a
recently developed general strategy for monitoring CD4 responses
that overcomes the need for prior knowledge of epitope or HLA
restriction to analyze a series of 31 cancer patients and healthy donors
for the presence of CD4T cells to NY-ESO-1, and related this response
to NY-ESO-1 expression in tumor cells and serum antibodies to
NY-ESO-1. None of the 18 patients that tested seronegative for
NY-ESO-1 had detectable CD4 T cell responses. On the contrary, 11
of 13 cancer patients with serum antibodies to NY-ESO-1 had poly-
clonal CD4 T cell responses directed against various known and
previously undescribed NY-ESO-1 epitopes. NY-ESO-1 peptide 80–109
was the most immunogenic, with 10 of 11 patients responding to this
peptide. We show here that 12-mer determinants from NY-ESO-1
eliciting a CD4 T cell response were peptide 87–98 with promiscuous
HLA class II presentation, peptide 108–119 restricted by HLA-DP4, and
peptides 121–132 and 145–156, both shorter epitopes from previously
described HLA-DR4 peptides, also presented by HLA-DR7. This study
represents the next step in compiling a comprehensive picture of the
adaptive immune response to NY-ESO-1, and provides a general
strategy for analyzing the CD4 T cell response to other tumor
antigens eliciting a humoral immune response.
NY-ESO-1 is a germ cell protein that is frequently expressed bycancer cells, but not normal somatic cells (1). It was discovered
by screening the serum of an esophageal cancer patient for anti-
bodies recognizing proteins expressed in autologous tumor cells.
Humoral and CD8 T cell responses to NY-ESO-1 are found in a
high frequency of patients with NY-ESO-1 tumors, making it one
of the most immunogenic human tumor antigens (2).
Immune responses to NY-ESO-1 are generally restricted to
patients with advanced cancer (3), and tend to disappear with tumor
resection or therapy-induced regression (4). A possible reason for
this dependence of NY-ESO-1 immunity on tumor size is that the
tumor must reach a critical mass before sufficient antigen is released
from necrotic areas of the tumor to prime antigen-presenting cells
(APC) and initiate B cell and T cell responses. In monitoring a large
series of cancer patients, we showed that humoral responses to
NY-ESO-1 correlated with the presence of peripheral CD8T cells
against NY-ESO-1 (5), suggesting the involvement of CD4 helper
T cells in coordinating this response. Furthermore, strong humoral
responses to NY-ESO-1 are of IgG isotype (3), rather than IgM,
which also predicts involvement of CD4 T cells. Helper T cells are
known to be critical for inducing class switching by B cells, and the
major pathway for class switching occurs through surface interac-
tionstimulation of CD40 with CD40L (6, 7), with additional
involvement of the more recently described molecule ICOS (8).
Independent of their helper role in humoral and CD8 T cell
responses, CD4 T cells also provide a protective function by
cytokine secretion and local inflammatory reactions, which has
been shown to be independent of the CD40–CD40L interaction (6).
It is thus interesting to determine whether CD4 T cell responses
to NY-ESO-1 correlate with the presence of antibody to NY-
ESO-1, as do CD8 T cell responses, or whether CD4 T cell
responses to NY-ESO-1 can be found more broadly in patients, as
a first line of specific immune recognition preceding the other
participants in the adaptive response.
CD4 T cell responses to NY-ESO-1 have been recently de-
scribed. Large epitopes restricted by HLA-DR4 (9–11) or promis-
cuous for several HLA-DR have been shown (12). HLA-DP4-
restricted responses were also seen and were suggested to correlate
with antibody status (13). Still, most approaches to study CD4 T
cells rely on the generation of T cell lines after multiple peptide
stimulations, which are typically assessed for bulk cytokine secre-
tion or proliferation. The lack of reliable and quantitative ap-
proaches for monitoring CD4 T cell responses has hindered the
analysis of larger series of patients.
We recently introduced a new methodology to analyze antigen-
specific CD4 T cells at the single cell level in enzyme-linked
immunospot (ELISPOT) assays (14). Responses of purified CD4
T cells to influenza nucleoprotein (NP) were assessed after a single
round of in vitro antigen stimulation to recall memory responses
only. Specific CD4T cells were detected not only against a peptide
containing HLA-DR promiscuous epitope, but also against full-
length NP expressed in APCs from recombinant fowlpox vectors.
Through the use of innovative targets, namely phytohemagglutinin-
expanded CD4 T cells (T-APC), ELISPOT assays could be
carried out with virtually no background, in a quantitative and
reproducible manner.
We show here that the same approach can be adapted to monitor
CD4 T cell responses to NY-ESO-1 in cancer patients, as a
counterpart to the general strategy that we previously developed to
monitor CD8 T cell responses to NY-ESO-1 in any patient (15).
Because our approach to CD4 T cell monitoring is not limited to
known epitopes, it is applicable to any patient regardless of HLA
restriction. In addition, it facilitates the discovery of new HLA class
II restricted peptides from NY-ESO-1.
Materials and Methods
Peptides, Protein, and Viral Vectors. The following peptides were
obtained from Bio-Synthesis (Lewisville, TX) with a purity of
90%: ESO80-109 (ARGPESRLLEFYLAMPFATPMEAEL-
Abbreviations: APC, antigen-presenting cell; ELISPOT, enzyme-linked immunospot; NP,
nucleoprotein; T-APC, target APC; CHP, hydrophobized polysaccharide pullulan; PBMC,
peripheral blood mononuclear cells; EBV, Epstein–Barr virus; EBV-B, EBV-transformed B
lymphocytes; AdESO, adenovirus recombinant for NY-ESO-1; FP-ESO, fowlpox virus recom-
binant for NY-ESO-1; FP-NP, fowlpox virus recombinant for influenza nucleoprotein.
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ARRSL), ESO87-98 (LLEFYLAMPFAT), ESO108-119 (SLAQ-
DAPPLPVP), ESO121-132 (VLLKEFTVSGNI), ESO143-154
(RQLQLSISSCLQ), ESO145-174 (LQLSISSCLQQLSLLMWI-
TQCFLPVFLAQP), and NP206-229 (FWRGENGRKTRIAY-
ERMCNILKGK). Peptide ESO79-109 (GARGPESRLLE-
FYLAMPFATPMEAELARRS) was obtained from Multiple
Peptide Systems (San Diego) with a purity 80%. Overlapping
18-mer peptides from NY-ESO-1 were described (9). Adenoviral
vector recombinant for NY-ESO-1 (AdESO) was obtained from
Genzyme Corporation (Framingham, MA), and fowlpox vectors
recombinant for NY-ESO-1 (FP-ESO) or for influenza nucleopro-
tein (FP-NP) were obtained from Therion Biologics (Cambridge,
MA), and their construction was previously described (14, 15). The
full-length recombinant NY-ESO-1 protein was expressed from
Escherichia coli (3) and complexed with hydrophobized polysac-
charide, pullulan (CHP) as described (16, 17).
In Vitro Sensitization with Peptides or Recombinant Adenovirus
Constructs. Peripheral blood mononuclear cells (PBMC) were
obtained with informed consent from cancer patients. HLA typing
of donor PBMCs or derived cell lines was done by sequence specific
oligonucleotide probing and sequence specific priming of genomic
DNA by using standard procedures. CD4 and CD8 T lympho-
cytes were separated from PBMCs by using antibody-coated mag-
netic beads (Dynabeads, Dynal, Oslo) and seeded into round-
bottomed 96-well plates (Corning) at a concentration of 5  105
cells per well in RPMI medium 1640 supplemented with 10%
human AB serum (GemCell, Gemini BioProducts, Woodland,
CA), L-glutamine (2 mM), penicillin (100 unitsml), streptomycin
(100gml), and 1% nonessential amino acids (complete medium).
As APC for antigen-specific presensitization, CD4CD8 PBMC
depleted of CD4 and CD8T cells were either pulsed with 10M
peptide or infected with recombinant adenovirus at 1,000 infectious
units per cell overnight at 37°C in 250 l of serum-free medium
(X-VIVO-15, Bio-Whittaker). Pulsed or infected CD4CD8
APC were then washed, irradiated, and added to plates containing
CD4 or CD8 T cells at a concentration of 1 106 APC per well.
After 8 h, IL-2 (10 unitsml, Roche Molecular Biochemicals) and
IL-7 (20 ngml, R & D Systems) were added to culture wells, and
this was repeated every 3–4 days thereafter.
Target Cells. A fraction of CD4 T cells from the initial separation
(see above) was seeded into 48-well plates (Corning) at a concen-
tration of 1  106 cells per ml in complete medium supplemented
with 10 gml phytohemagglutinin (HA15, Murex Diagnostics,
Dartford, U.K.). Cells were fed and expanded twice a week with
complete medium containing IL-2 (10 unitsml) and IL-7 (20
ngml). The activated T cell APC (T-APC) were typically harvested
and used as target cells after 20–30 days of culture.
Epstein–Barr virus (EBV)-transformed B lymphocytes (EBV-B
cells) were cultured in RPMI medium 1640 supplemented with 10%
FCS (Summit Biotechnology, Ft. Collins, CO), L-glutamine (2
mM), penicillin (100 unitsml), streptomycin (100 gml), and 1%
nonessential amino acids.
In all assays, target cell APC were washed twice in X-VIVO-15
medium to remove serum. Peptides (10 M) or recombinant
fowlpox virus (100 plaque forming units per cell) were then added
and target cells were incubated overnight at 37°C. At the end of this
incubation period, target cell APC were washed twice and resus-
pended in RPMI for testing.
ELISPOT Assays. Flat-bottomed, 96-well nitrocellulose plates
(MultiScreen-HA, Millipore) were coated with IFN- mAb (2
gml, 1-D1K, Mabtech, Stockholm) and incubated overnight at
4°C. After washing with RPMI, plates were blocked with 10%
human AB type serum for 2 h at 37°C. Presensitized CD4 T
effector cells (5 104 or 1 104) and 1 105 target cells (T-APC
or EBV-B cells) were added to each well and incubated for 20 h in
RPMI medium 1640 without serum. For blocking experiments, 10
gml of the indicated antibodies were added at culture initiation.
Plates were then washed thoroughly with water containing 0.05%
Tween 20 to remove cells, and IFN- mAb (0.2 gml, 7-B6-1-
biotin; Mabtech) was added to each well. After incubation for 2 h
at 37°C, plates were washed and developed with streptavidin-
alkaline phosphatase (1 gml; Mabtech) for 1 h at room temper-
ature. After washing, substrate (5-bromo-4-chloro-3-indolyl phos-
phatenitroblue tetrazolium; Sigma) was added and incubated for
5 min. After final washes, plate membranes displayed dark-violet
spots that were scanned and counted by using CTL ImmunoSpot
analyzer and software (Cellular Technologies, Cleveland).
Results
Specificity of Presensitization with Peptides or Recombinant Viral
Vectors. Melanoma patient NW-29 was previously shown to have a
spontaneous CD4T cell response to NY-ESO-1 peptides 115-132,
121-138, and 139-156 (9), and was thus selected as a control for our
monitoring approach. CD4 T lymphocytes were stimulated with
autologous CD4CD8-depleted PBMC pulsed with either peptides
from NY-ESO-1 or Influenza NP, or infected with viral vectors
recombinant for full-length NY-ESO-1 or NP sequences. After 3
weeks of culture without additional restimulation, presensitized
CD4 T cell effectors were tested by ELISPOT assay against
autologous phytohemagglutinin-activated CD4 T blasts (T-APC)
pulsed with various peptides.
We confirmed that CD4 T cells from patient NW-29 were
reactive against influenza NP peptide 206-229, previously shown to
be immunogenic in a majority of patients. A large number of IFN-
producing CD4 T cells specific for NP206-229 could be detected
after presensitization with NP206-229, with low background against
irrelevant NY-ESO-1 peptides (Fig. 1).
Next, we tested the immunogenicity of a known HLA class II
NY-ESO-1 epitope and found that CD4 T cells from patient
NW-29 presensitized with NY-ESO-1 peptide 115-132 specifically
produced IFN- in response to 115-132, but not to control peptides
NY-ESO-1 145-174 nor NP 206-229 (Fig. 1). Unexpectedly, 115-
132-presensitized cells also had significant reactivity against NY-
ESO-1 polypeptide 80-109. To ask whether this reactivity was
potentially related to a novel NY-ESO-1 specificity of CD4 T cells
from patient NW-29, CD4 T cells were presensitized with peptide
80-109. The reactivity to 80-109 was very strong, comparable to that
against 115-132 albeit with higher nonspecific background, thus
revealing a new epitope spontaneously immunogenic in patient
NW-29 (Fig. 1). Peptide 80-109 could be titrated down to 100 nM
Fig. 1. Specificity controls of CD4 T cell presensitization from melanoma
patient NW29. CD4 T cells were presensitized with indicated peptides or recom-
binant vectors and tested by ELISPOT at d23 against autologous T-APC pulsed
with peptides NP206-229, ESO115-132, ESO80-109, or ESO145-174. Results rep-
resent the mean number of spots per 50,000 effector CD4 T cells in duplicate
wells, with error bars indicating standard deviation.









(Fig. 2A), and its recognition was blocked by antibodies against
HLA-DR, but not against HLA class I (Fig. 2B).
General Strategy for CD4 T Cell Monitoring. To monitor patients
CD4 T cell responses regardless of specific HLA restriction or
knowledge of defined epitopes, we adapted the general strategy
developed for CD8 T cell responses to NY-ESO-1 (15). This
strategy was validated with a recombinant fowlpox vector used to
introduce the full-length influenza NP sequence (FP-NP) in CD4
CD8-depleted cells, which in turn naturally process NP into class II
epitope presented to CD4 T cells. Although not as efficient as
presensitization with peptide NP206-229, presensitization with
FP-NP was able to significantly recall CD4 T cells specific for
NP206-229 from patient NW29 (Fig. 1).
Three different vectors coding for full-length NY-ESO-1 were
then compared for CD4 T cell presensitization: fowlpox virus
(FP-ESO), vaccinia virus (v.v.ESO), and adenovirus (AdESO).
Presensitization with FP-ESO was able to recall both specificities
against ESO80-109 and ESO115-132, showing that the introduced
NY-ESO-1 sequence had been naturally processed in endogenous
pathways (Fig. 1). Recombinant vaccinia only recalled ESO115-
132, thus exhibiting a differential pattern of processing or immu-
nodominance specific to vaccinia vector, or simply lower general
reactivity. Finally, presensitization with AdESO gave the highest
responses to both immunogenic peptides, but not to control NP
peptide or NY-ESO-1 peptide 145-174, which is not recognized in
this patient (Fig. 1).
Different Routes of Class II Presentation and Characterization of
12-Mer Epitopes. This general strategy of monitoring CD4 T cell
responses to NY-ESO-1 regardless of the patient HLA haplotype
or known epitopes was further pursued. Ovarian cancer patient
NW1558 CD4 T cells were presensitized with AdESO and tested
by ELISPOT against autologous T-APC infected with FP-ESO or
control FP-NP. Fowlpox was chosen over soluble protein to deliver
NY-ESO-1 to T-APC, to avoid relying on the uptake capacity of
target cells, and because it gave the most consistent results com-
pared with other vectors such as vaccinia (not shown). From patient
NW1558, a clear response specific for NY-ESO-1 was detected
without the need to define HLA restriction usage (Fig. 3). To
determine the epitope(s) responsible for CD4 T cell recognition,
we tested a 30-mer polypeptide from NY-ESO-1, 100-129, and
found that it was very reactive with AdESO-presensitized CD4 T
cells (Fig. 3). The epitope was further mapped by using 18-mer
overlapping peptides in the 100-129 region, and peptides 103-120
and 109-126 were still recognized (Fig. 4A). Finally, we searched for
presence of HLA class II binding motif within these sequences by
using a web-based predictive algorithm (18) and determined from
potential anchor motifs that 12-mer peptide 108-119 would likely be
long enough to contain the epitope and bind to HLA class II.
Indeed, we confirmed that AdESO-presensitized CD4 T cells
recognized NY-ESO-1 peptide 108-119, and that both polypeptide
100-129 and 12-mer 108-119 were immunogenic when used to
presensitize NW1558 CD4 T cells (Fig. 3).
As an alternative to infectious delivery of NY-ESO-1 for HLA
class II presentation, we assessed soluble full-length NY-ESO-1
recombinant protein complexed with hydrophobized polysaccha-
ride pullulan (ESO-CHP) for presensitizing patient CD4 T cells
(17). From melanoma patient NW903, we found that ESO-CHP
could efficiently stimulate CD4T cells that recognized NY-ESO-1
recombinant fowlpox-infected targets, and we mapped the associ-
ated peptide epitope to polypeptide 80-109 (Fig. 4B). Within this
30-mer peptide, we found that 18-mer peptide 85-102 was still
antigenic (not shown), and by using the predictive algorithms (18),
determined that 87-98 was a 12-mer peptide still containing the
epitope (Fig. 4B).
Similarly, we stimulated CD4 T cells from melanoma patient
NW634 with ESO-CHP and mapped one of the recognized
epitopes to NY-ESO-1 peptide 157-174, which was previously
shown to be presented by HLA-DP4 (Fig. 4C).
Finally, we found that, after presensitization with NY-ESO-1-
recombinant adenovirus, peptides 115-132, 121-138, and 139-156
were antigenic in patient NW29 (Fig. 1 and data not shown), and
mapped 12-mer epitopes still recognized within these peptides to
121-132 and 143-154 based on predictive algorithms (Fig. 4D and
data not shown).
HLA Class II Restriction of NY-ESO-1 Epitopes. Recognition of NY-
ESO-1 peptide 80-109 by CD4 T cells from patient NW1454 was
analyzed to determine the HLA class II allele used for presentation.
Partially histocompatible EBV-B cells transduced with NY-ESO-1
recombinant fowlpox or control NP fowlpox were used to find
matching HLA class II alleles able to present NY-ESO-1. We found
that, in most cases, 80-109-specific CD4 T cells recognized HLA-
Fig. 2. (A) Titration of peptide ESO80-109 recognized by CD4 T cells from
patient NW29. CD4 T cells were presensitized with peptide ESO80-109 and
tested by ELISPOT against autologous T-APC pulsed with peptide ESO80-109 in
concentrations ranging from 100 M to 1 nM, or not pulsed. (B) Blocking of
ESO80-109 recognition by anti-HLA-DR antibodies. The same effectors were
tested by ELISPOT against targets pulsed with ESO80-109 or irrelevant control
peptide NP206-229 in the presence or absence of anti-HLA-DR (10 gml) or
anti-HLA class I (10 gml) monoclonal antibodies. Results represent the mean
numberof spotsper50,000effectorCD4Tcells induplicatewells,witherrorbars
indicating standard deviation.
Fig. 3. Presensitization of CD4 T cells from ovarian cancer patient NW1558.
CD4 T cells were presensitized with AdESO or with peptides ESO100-129 or
ESO108-119 and tested by ELISPOT at d19 against autologous T-APC pulsed with
ESO98-105,ESO108-119,orESO100-129,or infectedwithFP-NPorFP-ESO.Results
represent the mean number of spots per 50,000 effector CD4 T cells in duplicate
wells, with error bars indicating standard deviation.
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DRB1*07 targets expressing NY-ESO-1, whereas other shared
alleles did not significantly present the epitope (Fig. 5A). However,
it could not be excluded that other alleles were responsible for the
presentation of 80-109 in different patients, because NW1558
appeared to favor HLA-DRB1*03 or HLA-DRB1*12 usage for
ESO80-109 presentation (Fig. 5B).
When similar approaches were used, responses to 121-132 and
143-154 were also found to be restricted by HLA-DRB1*07 in
patient NW29 (not shown), and HLA-DPB1*04 appeared to be
responsible for presentation of peptide 100-129, and thus likely for
smaller epitope 108-119, in patient NW1558 (Fig. 5C).
Correlation of Antibody and CD4 T Cell Responses to NY-ESO-1. To
obtain a comprehensive picture of CD4 T cell reactivity against
NY-ESO-1, we analyzed a large series of cancer patients and
healthy donors, selected according to their serological status for
NY-ESO-1, and tested for their capacity to respond to NY-
ESO-1 immunogenic polypeptide 80-109 or to full-length NY-
ESO-1. After presensitization, CD4 T cells were tested against
autologous or histocompatible targets pulsed with polypeptide
80-109 or a negative control peptide, or infected with fowlpox
recombinant for NY-ESO-1 or for control influenza NP. T-APC
were used for peptide pulsed targets, because they usually
evoked very low nonspecific background, and B-EBV were used
for recombinant fowlpox infection, because responses were
usually stronger than with infected T-APC, albeit with higher
background too.
We found that there was a complete correlation between the
presence of CD4 T cell and antibody responses to NY-ESO-1 in
the 31 patients tested (Table 1). No NY-ESO-1 seronegative patient
or healthy donor had demonstrable CD4 reactivity to NY-ESO-1.
Among NY-ESO-1 antibody responders, 11 of 13 patients had
CD4 T cells reactive with polypeptide 80-109, either as an im-
munogen or as an antigen. Patient NW1557 could not be evaluated
because of unexplained high background on autologous targets.
Patient NW783 appeared negative despite a humoral response to
NY-ESO-1. All patients responding to peptide 80-109 were capable
of recognizing full-length NY-ESO-1 naturally processed from
recombinant fowlpox (Table 1). In additional tests, patients NW29,
NW903, NW1374, NW1454, and NW1558 all recognized shorter
Fig. 4. Mapping of epitopes recognized by CD4 T cells from different cancer
patients. (A) CD4 T cells from patient NW1558 were presensitized with adeno-
virus recombinant for NY-ESO-1 (AdESO) and tested by ELISPOT against histo-
compatible EBV-B cells pulsed with indicated 18-mer NY-ESO-1 peptides, or
infected with recombinant fowlpox. (B) CD4 T cells from patient NW903 were
presensitized with ESO-CHP and tested by ELISPOT against histocompatible
EBV-B cells pulsed with indicated NY-ESO-1 peptides, or infected with recombi-
nant fowlpox. (C) CD4 T cells from patient NW634 were presensitized with
ESO-CHP and tested by ELISPOT against histocompatible EBV-B cells pulsed with
indicated NY-ESO-1 peptides. (D) CD4 T cells from patient NW29 were presen-
sitized with AdESO and tested by ELISPOT against histocompatible EBV-B cells
pulsed with indicated NY-ESO-1 peptides, or infected with recombinant fowlpox.
Fig. 5. HLA restriction usage for presentation of NY-ESO-1 to CD4 T cells
specific for ESO80-109 and ESO100-129. (A) CD4 T cells from patient NW1454
(HLA-DRB1*07,15; -DQB1*02,06; -DPB1*04,09) were presensitized with peptide
ESO80-109 and tested by ELISPOT against partially histocompatible EBV-B cells
infected with NY-ESO-1 or NP recombinant fowlpox vectors. HLA class II alleles
shared between effectors and targets are indicated. *DPnt: targets not tested for
HLA-DP compatibility with effectors. (B) Similar analysis with CD4 T cells from
patient NW1558 (HLA-DRB1*03,12; -DQB1*02,03; -DPB1*04,10) presensitized
with peptide ESO80-109. (C) Similar analysis with CD4 T cells from patient
NW1558 presensitized with peptide ESO100-129. Results represent the mean
number of spots per 50,000 effector CD4T cells in duplicate wells with error bars
indicating standard deviation.









NY-ESO-1 peptides 85-102 or 87-98, contained within 80-109 (Fig.
4 and data not shown).
Patient NW903 surprisingly failed to respond to 80-109 after
peptide presensitization, but did so after ESO-CHP presensitiza-
tion. Patients NW1454 and NW1567 failed to respond to AdESO
presensitization despite specific responses after presensitization
Table 1. Analysis of CD4 T cell responses of cancer patients and healthy donors in response to NY-ESO-1
peptide or recombinant full-length antigen





No. of spots against T-APC*
80-109 (control)
No. of spots against EBV-B†
FP-ESO (FP-NP)
NW29 Melanoma  80-109 684 (3) 165 (8)
Ad-ESO 207 (2) 355 (11)
NW634 Melanoma  80-109 425 (0) ND
ESO-CHP 105 (2) 163 (36)
NW783 Melanoma  80-109 0 (0) ND
FP-ESO 0 (0) ND
NW903 Melanoma  80-109 21 (0) ND
ESO-CHP 314 (19) 270 (30)
NW1289 NSC Lung Ca.  80-109 519 (19) 171 (38)
Ad-ESO 166 (4) 237 (30)
NW1307 Schwannoma  80-109 185 (5) ND
FP-ESO 5 (1) 111 (19)
NW1374 NSC lung Ca.  80-109 84 (7) ND
FP-ESO 1 (3) ND
NW1454 Melanoma  80-109 334 (3) 409 (28)
Ad-ESO 30 (7) 32 (21)
NW1557 Esophageal Ca.  80-109 132 (163) 55 (51)
Ad-ESO 39 (60) 36 (26)
NW1558 Ovarian Ca.  80-109 457 (0) 105 (4)
Ad-ESO 370 (0) 606 (18)
NW1567 Ovarian Ca.  80-109 78 (3) 98 (64)
Ad-ESO 0 (0) 1 (5)
SS4 Synovial sarcoma  79-108 519 (3) 61 (13)
Ad-ESO 37 (0) 229 (27)
LU-89 NSC lung Ca.  80-109 801 (12) 54‡ (9)
NW208 Melanoma  80-109 6 (7) 25 (15)
Ad-ESO 4 (4) 38 (48)
NW415 Melanoma  80-109 1 (0) 115 (77)
Ad-ESO 6 (7) 33 (18)
NW681 Melanoma  80-109 7 (8) 11 (33)
Ad-ESO 9 (9) 13 (17)
NW792 Melanoma  80-109 0 (0) 20 (13)
Ad-ESO 0 (0) 26 (26)
NW886 Melanoma  80-109 5 (3) 249 (269)
Ad-ESO 0 (1) 31 (31)
NW1028 Melanoma  80-109 2 (2) 1 (5)
Ad-ESO 2 (2) 3 (7)
LU-82 NSC lung Ca.  80-109 0 (0) ND
LU-86 NSC lung Ca.  80-109 4 (3) ND
LU-279 NSC lung Ca.  80-109 3 (1) ND
LU-281 NSC lung Ca.  80-109 2 (2) ND
LU-346 NSC lung Ca.  80-109 0 (0) ND
LU-395 NSC lung Ca.  80-109 0 (0) ND
LU-400 NSC lung Ca.  80-109 0 (0) ND
LU-449 NSC lung Ca.  80-109 0 (2) ND
NC111 Healthy donor  80-109 0 (0) ND
NC189 Healthy donor  80-109 3 (2) ND
NC201 Healthy donor  80-109 3 (0) ND
NC200 Healthy donor  80-109 0 (0) ND
CD4 T cells were tested 20–30 days after presensitization. Boldface indicates significant difference compared to negative control (in
parentheses). Results are representative of at least two separate reproducible ELISPOT assays. ND, not done; NSC lung Ca. non-small-cell
lung cancer; Ca., cancer.
*CD4T cells (50,000) presensitized with ESO80-109 or full-length NY-ESO-1 recombinant antigen were tested against T-APC pulsed with
peptide 80-109 (or negative control peptide).
†CD4 T cells (10,000) presensitized with ESO80-109 or full-length NY-ESO-1 recombinant antigen were tested against EBV-B cells
infected with NY-ESO-1 recombinant fowlpox FP-ESO (or control NP recombinant fowlfox FP-NP).
‡Tested on autologous T-APC infected with FP-ESO or FP-NP, not EBV-B.
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with NY-ESO-1 polypeptide 80-109. Patients NW1307 and SS4
appeared to preferentially respond to an epitope different from
80-109 after FP-ESO presensitization (we found that peptides
145-174 and 157-170 were respectively recognized in further tests
not shown), even though ESO80-109 was also immunogenic on its
own after peptide presensitization (Table 1).
Among responder patients, NW29, NW634, NW1307, NW1558,
and SS4 were found to have polyclonal CD4 responses against at
least two different NY-ESO-1 epitopes.
Discussion
Based on the remarkably high percentage of patients with advanced
cancers developing NY-ESO-1 specific antibodies and CD8T cells
in response to their own tumors (3, 5), NY-ESO-1 can be consid-
ered one of the most immunogenic human tumor antigens defined
to date. The strength of NY-ESO-1 CD8 responses is comparable
to that of influenza memory effectors, as measured in vitro.
With the development of a new methodology to monitor CD4
responses in an indirectly quantitative procedure similar to CD8
analysis (14), we found that the comparison to influenza was still
valid with regard to the extraordinary strength of NY-ESO-1 CD4
T cell responses. Most importantly, CD4 reactivity was tightly
associated with the NY-ESO-1 antibody status of patients. Effec-
tors analyzed in this study have been primed in vivo, and responses
were not induced de novo from patients seronegative for NY-
ESO-1. In contrast to other disease settings where CD4 responses
are detected in the absence of antibodies or CD8 T cells to a
specific antigen (19), NY-ESO-1 expression in tumors appears to
induce an integrated immune response in vivo. These findings can
be compared with high levels of antibodies, CD4, and CD8 T
cells seen against HIV (20). In this context, successful viral and
tumor protection in animal models is known to be associated with
integrated immune responses (21, 22). CD4 T cells are critical in
mediating this protective immunity (23), and are essential for the
development of functional CD8 T cell memory (24). Recently, it
was shown that CD4 help is required to induce CD8 responses
through an indirect pathway of cross-presentation from tumor cells
(25), thus favoring the hypothesis that local APCs take up the
antigen to prime T cells rather than by direct presentation from
tumor cells. The strong humoral response to NY-ESO-1 may
greatly facilitate antigen uptake by APC with the resulting priming
and cross-presentation leading to and maintaining a vigorous CD4
and CD8 T cell response to NY-ESO-1. This idea is supported
by in vitro findings that NY-ESO-1 proteinantibody complexes
are efficiently captured by dendritic cells for presentation to T
cells (26).
Determining novel NY-ESO-1 epitopes proved relatively
straightforward when our recently developed general strategy for
CD4 monitoring in donors of any HLA haplotype was used (14).
Many patients developed simultaneous responses to several
epitopes, with no clear evidence of immunodominance. The central
and N-terminal sequence of NY-ESO-1 appeared very rich in
epitopes for CD4 T cell recognition, as determined in this study
with 12-mer immunogenic peptides: 87-98, 108-119, 121-132, and
143-154, which together with HLA-DP4 binding peptide 157-170
span this region of NY-ESO-1 in a nearly contiguous fashion
(Fig. 6).
Notably, the most immunogenic peptide, NY-ESO-1 80-109, was
found associated with multiple HLA class II restrictions. Its asso-
ciation with surface molecules other than MHC products should be
explored to determine whether HLA class II promiscuity alone
explains its high level of immunogenicity in antibody-positive
patients.
The analysis of the class of Ig induced by NY-ESO-1 may also
provide some clues about the in vivo function of CD4 T cells. In
diseases driven by type 1 immunity such as multiple sclerosis (27)
or Lyme borreliosis (28), an association was found with specific Ig
subclasses. From our preliminary data, a majority of patients
develop Th1-related IgG1 isotype against NY-ESO-1, which ap-
pears in accordance with the presence of IFN--producing CD4
T cells specific for NY-ESO-1 derived from these patients.
The development of a general strategy to monitor CD4 and
CD8 T cells against NY-ESO-1 in seropositive patients provides
us with the methodology to now look for cellular responses to the
large array of other serologically defined tumor antigens
(www2.licr.orgCancerImmunomeDB).
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